Transgenic mice with liver-specific overexpression of Lpl develop liver-specific lipid accumulation and liver-specific insulin resistance [56], and patients with conditions that results in Lpl mutation (hyperlipoproteinemia type 1) that lower Lpl expression is prone to developing insulin resistance, not necessarily specific to the liver [57]. Here, LPL is linked to Hyperlipoproteinemia type 1.